{
    "nctId": "NCT04143282",
    "briefTitle": "Evaluation of the Effect of Metformin on Metastatic Breast Cancer as Adjuvant Treatment",
    "officialTitle": "Evaluation of the Effect of Metformin on Metastatic Breast Cancer as Adjuvant Treatment",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 250,
    "primaryOutcomeMeasure": "The radiologic response rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* The non-diabetic patients will be included in the study if they meet the following criteria:\n\n  1. Confirmed metastatic breast cancer (IV stage) radiologically or by clinical evaluation receiving chemotherapy\n  2. Age between 18- 70 years.\n  3. Life expectancy at least 6 months\n\nExclusion Criteria:\n\n* The patients will be excluded from the study if they have the following criteria:\n\n  1. Bad prognosis disease: Criteria defined as the following\n\n     * If patient \\>70 years\n     * If patient has bad site metastasis (brain)\n  2. Hypersensitivity for metformin: if happened patient will be treated as following\n\n     \u2022 Pheniramine Maleate 3 times daily for 7 days and Tablet Dexamethasone 1mg daily in 2 divided doses for 5 days \\[16\\].\n  3. Any condition associated with increased risk of metformin-associated lactic acidosis (e.g., congestive heart failure defined as New York Heart Association {NYHA} Class III or IV functional status; the history of acidosis of any type, severe infections, kidney or liver disease, respiratory disease, seizures .\n  4. Diabetic patients.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}